APYX - NASDAQ
Apyx Medical Corporation
$3.79
-0.26%Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
At a Glance
Live SnapshotApyx Medical Corporation Management Team
Mr. Matthew C. Hill CPA
Chief Financial Officer, Treasurer & Secretary
Compensation
$500,436
Mr. Shawn D. Roman
Chief Operating Officer
Compensation
$332,328
Ms. Dolores Catania
Chief of Confidence
Mr. Stavros George Vizirgianakis B.Com.
Executive Chairman
Compensation
$27,116
Mr. Charles D. Goodwin II
President, Chief Executive Officer & Director
Compensation
$522,698
Mr. Moshe Citronowicz
Senior Vice President
Compensation
$349,175
Apyx Medical Corporation Insider Positioning
During the last 12 months, there has been no insider trading activity reported for APYX.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
APYX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | June 25, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 25, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 23, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 24, 2022 | December 31, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 25, 2021 | December 31, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | June 26, 2020 | August 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 21, 2019 | August 01, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | July 27, 2018 | July 27, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | August 07, 2017 | September 14, 2017 | 2017 | |
DEF 14A DEF 14A 2017 N/A | July 28, 2017 | September 14, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.